Prot #CX-228-301: A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-mutated and wild-type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/8/22 → 3/31/23

Funding

  • Calithera Biosciences, Inc. ((OE) Prot #CX-228-301)